CD274 and nonpapillary renal cell carcinoma: Another study based on VEGFR TKI therapy on 53 metastatic ccRCC patients revealed undesirable outcomes in a group of patients whose tumors had an intense Th1-oriented inflammatory and suppressive immune environment, with high levels of PD-1/PD-L1 [39].